Regulatory Ahead of ASCO data drop, AZ gets key Imfinzi approval PharmaphorumAstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.OncologyRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaphorum AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease. Oncology Read full story Post navigation Previous: Medicare Advantage Out-of-Pocket Limits: Variation and TrendsNext: GSK’s Nucala secures NICE COPD endorsement Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026